Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?

Diabetic Medicine

Volumn 25, Issue 7, 2008, Pages 788-791

  Karlsson, E ^a   Shaat, N ^a   Groop, L ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomarker; Complement factor; Diabetes mellitus; Maturity onset diabetes of the young; Ttransthyretin

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C8; GLYCOSYLATED HEMOGLOBIN; PREALBUMIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HNF1A PROTEIN, HUMAN; HNF4A PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; GENE; GENE MUTATION; HEPATOCYTE NUCLEAR FACTOR 1ALPHA GENE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA GENE; HUMAN; HYPERGLYCEMIA; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; AGED; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPLEMENT C5; COMPLEMENT C8; DIABETES MELLITUS, TYPE 2; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; MIDDLE AGED; MUTATION; PREALBUMIN; TRANS-ACTIVATORS;

EID: 49649102433     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02467.x     Document Type: Article

References (11)

1. Wilce JA, Daly NL, Craik DJ. Synthesis and structural analysis of the N-terminal domain of the thyroid hormone-binding protein transthyretin. Clin Chem Lab Med 2002; 40: 1221-1228.
2. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver-specific nuclear factor with the fibrinogen and α1-anti-trypsin promoters. Science 1987; 238: 688-692.
3. Alper CA, Raum D, Awdeh ZL, Petersen BH, Taylor PD, Starzl TE. Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, α1-anti-trypsin, C8, and factor B. Clin Immunol Immunopathol 1980; 16: 84-89.
4. Frain M, Swart G, Monaci P, Nicosia A, Stampfli S, Frank R et al. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 1989; 59: 145-157.
5. Pontoglio M, Pausa M, Doyen A, Viollet B, Yaniv M, Tedesco F. Hepatocyte nuclear factor 1α controls the expression of terminal complement genes. J Exp Med 2001; 194: 1683-1689.
6. Shih DQ, Stoffel M. Dissecting the transcriptional network of pancreatic islets during development and differentiation. Proc Natl Acad Sci U S A 2001; 98: 14189-14191.
7. Glucksmann MA, Lehto M, Tayber O, Scotti S, Berkemeier L, Pulido JC et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes 1997; 46: 1081-1086.
8. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005; 54: 570 -575.
9. Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41: 467-473.
10. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999; 13: 273-279.
11. Jain SK, McVie R, Duett J, Herbst JJ. The effect of glycemic control on plasma prealbumin levels in Type 1 diabetic children. Horm Metab Res 1993; 25: 102-104.